Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Masuda T, et al. Among authors: miura y. Clin Transl Oncol. 2015 Sep;17(9):702-9. doi: 10.1007/s12094-015-1297-8. Epub 2015 May 20. Clin Transl Oncol. 2015. PMID: 25990507
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Yamaguchi O, et al. Among authors: miura y. Cancer Chemother Pharmacol. 2019 May;83(5):817-825. doi: 10.1007/s00280-019-03790-w. Epub 2019 Feb 13. Cancer Chemother Pharmacol. 2019. PMID: 30758646
Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
Uchida T, Kaira K, Yamaguchi O, Mouri A, Shiono A, Miura Y, Hashimoto K, Nishihara F, Murayama Y, Kobayashi K, Kagamu H. Uchida T, et al. Among authors: miura y. Thorac Cancer. 2019 Apr;10(4):975-979. doi: 10.1111/1759-7714.13039. Epub 2019 Mar 12. Thorac Cancer. 2019. PMID: 30864291 Free PMC article.
Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Yamaguchi O, Kaira K, Hashimoto K, Mouri A, Miura Y, Shiono A, Nishihara F, Murayama Y, Noda SE, Kato S, Kobayashi K, Kagamu H. Yamaguchi O, et al. Among authors: miura y. Thorac Cancer. 2019 Apr;10(4):992-1000. doi: 10.1111/1759-7714.13044. Epub 2019 Mar 19. Thorac Cancer. 2019. PMID: 30888716 Free PMC article.
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Murayama Y, Kaira K, Kobayashi K. Kagamu H, et al. Among authors: miura y. Cancer Immunol Res. 2020 Mar;8(3):334-344. doi: 10.1158/2326-6066.CIR-19-0574. Epub 2019 Dec 23. Cancer Immunol Res. 2020. PMID: 31871122
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
Yamaguchi O, Kaira K, Kawasaki T, Mouri A, Hashimoto K, Shiono A, Shinomiya S, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Mochida S, Kagamu H. Yamaguchi O, et al. Among authors: miura y. Thorac Cancer. 2020 Apr;11(4):1045-1051. doi: 10.1111/1759-7714.13363. Epub 2020 Feb 18. Thorac Cancer. 2020. PMID: 32068351 Free PMC article. Clinical Trial.
3,563 results